中康控股(2361.HK)今日掛牌上市 2021年營收3.24億元
格隆匯7月12日丨醫療數據提供商中康控股今日在港掛牌上市,每股發售股份定價為5.36港元。中康控股本次全球發售共發售7500萬股。香港公開發售獲2.21倍認購,國際發售部分獲1.36倍認購。此次淨籌預計約為3.554億港元。財務數據方面,得益於近年醫藥健康行業的蓬勃發展,中康控股的經營成績持續穩定增長。2019年-2021年,中康控股實現營收1.78億元、2.02億元、3.24億元;實現盈利5437.9萬元、6532.9萬元、7197.8萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.